CD4 cell recovery in treated HIV-2-infected adults is lower than expected: Results from the French ANRS CO5 HIV-2 cohort

AIDS

Volumn 20, Issue 3, 2006, Pages 459-462

  Matheron, Sophie ^a   Damond, Florence ^a   Benard, Antoine ^b   Taieb, Audrey ^b   Campa, Pauline ^a   Peytavin, Gilles ^a   Pueyo, Sophie ^b   Brun Vezinet, Francoise ^a   Chene, Genevieve ^b  

^a BICHAT HOSPITAL   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CELL COUNT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANK SUM TEST; VIRUS LOAD;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; DISEASE PROGRESSION; HIV INFECTIONS; HIV-2; HUMANS; VIRAL LOAD;

EID: 33645024195     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000199829.57112.2f     Document Type: Article

References (27)

1. Matheron S, Pueyo S, Damond F, Simon F, Leprêtre A, Campa P, et al. Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort. AIDS 2003; 17:2593-2601.
2. Damond F, Collin G, Descamps D, Matheron S, Pueyo S, Taieb A, et al. Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay. J Clin Microbiol 2005; 43:4234-4236.
3. Katlama C, Dominguez S, Gourlain K, Duvivier C, Delaugerre C, Legrand M, et al. Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097). AIDS 2004; 18:217-226.
4. Mullins C, Eisen G, Popper S, Dieng Sarr A, Sankale JL, Berger JJ, et al. Highly active antiretroviral therapy and viral response in HIV type 2 infection. Clin Infect Dis 2004; 38:1771-1779.
5. Clark NM, Dieng Sarr A, Sankale JL, Kanki RJ, Kazanjian P, Winfield R, Markovitz DM. Immunologic and virologic response of HIV-2 infection to antiretroviral therapy. AIDS 1998; 12:2506-2507.
6. Houston SC, Miedzinski LJ, Mashinter LD. Rapid progression of CD4 cell decline and subsequent response to salvage therapy in HIV-2 infection. AIDS 2002; 16:1189-1191.
7. Smith NA, Shaw T, Berry N, Vella C, Okorafor L, Taylor D, et al. Antiretroviral therapy for HIV-2 infected patients. J Infect 2001; 42:126-133.
8. Van der Ende ME, Brinkman K, Keuters M, Prins JM, Danner SA, Osterhaus ADME, Schutten M. Antiretroviral therapy in HIV2 infected patients in the Netherlands: results in 17 patients [Abstract P306]. AIDS 2000; 14 (Suppl. 4):S104.
9. Adje-Toure CA, Cheingsong R, Garcia-Lerma JG, Eholie S, Borget M-Y, Bouchez J-M, et al. Antiretroviral therapy in HIV-2- infected patients: Changes in plasma viral load, CD4+ cells counts and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire. AIDS 2003; 17 (Suppl. 3):S49-S54.
10. Ayanian JZ, Maguire JH, Marlink RG, Essex M, Kanki PJ. HIV-2 infection in the United States. N Engl J Med 1989; 320:1422-1423.
11. Gathe JC Jr, Ive P, Wood R, Schurmann D, Bellos NC, De Jesus E, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 2004; 18:1529-1537.
12. Squires K, Lazzarin A, Gatell JM, Powderly WG, Pokrovskiy V, Delfraissy JF, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004; 36:1011-1019.
13. Benson CA, Deeks SG, Brun SC, Gulick RM, Eron JJ, Kessler HA, et al. Safety and antiviral activity at 48 weeks of lopinavir/ ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis 2002; 185:599-607.
14. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA III et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850-1861.
15. Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine MD, Costagliola D, Weiss L. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000; 133:401-410.
16. Piketty C, Castiel P, Belec L, Batisse D, Si Mohamed A, Gilquin J, et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS 1998; 12:745-750.
17. Florence E, Lundgren J, Dreezen C, Fisher M, Kirk O, Blaxhult A, et al. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the Euro-SIDA study. HIV Med 2003; 4:255-262.
18. Benveniste O, Flahault A, Rollot F, Elbim C, Estaquier J, Pedron B, et al. Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. J Infect Dis 2005; 191:1670-1679.
19. Michel P, Balde AT, Roussilhon C, Aribot G, Sarthou JL, Gougeon ML. Reduced immune activation and T cell apoptosis in human immunodeficiency virus type 2 compared with type 1: correlation of T cell apoptosis with beta2 microglobulin concentration and disease evolution. J Infect Dis 2000; 181:64-75.
20. Alatrakchi N, Damond F, Matheron S, Beretta-Tempelhoff S, Campa P, Carcelain C, et al. Proliferative, IFNg and IL-2 producing T-cell responses to HIV-2 in untreated HIV-2 infection. AIDS 2005; 19: in press.
21. Damond F, Brun-Vezinet F, Matheron S, Peytavin G, Campa P, Pueyo S, et al. Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors. J Clin Microbiol 2005; 43: 484-487.
22. Colson P, Henry M, Tourres C, Lozachmeur D, Gallais H, Gastaut JA, et al. Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France. J Clin Microbiol 2004; 42:570-577.
23. Pieniazek D, Rayfield M, Hu D, Nkengasong JN, Soriano V, Heneine W, et al. HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1. AIDS 2004; 18:495-502.
24. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 2004; 9:57-65.
25. Andersson S, Norrgren H, da Silva Z, Biague A, Bamba S, Kwok S, et al. Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection. Arch Intern Med 2000; 160:3286-3293.
26. Simon F, Matheron S, Tamalet C, Loussert-Ajaka I, Bartczak S, Pepin JM, et al. Cellular and plasma viral load in patients infected with HIV-2. AIDS 1993; 7:1411-1417.
27. Damond F, Descamps D, Farfara I, Telles JN, Puyeo S, Campa P, et al. Quantification of proviral load of human immunodeficiency virus type 2 subtypes A and B using real-time PCR. J Clin Microbiol 2001; 39:4264-4268.